Effort is Launched With UC Davis Collaboration
RANCHO CORDOVA, Calif., Feb. 6 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (NASDAQ:KOOL) , a leading supplier of innovative products and services that process and store adult stem cells for treatment of disease and injury, today announced a regenerative medicine initiative in the veterinary market.
The Company has created a wholly-owned subsidiary, Vantus, Inc., a veterinary stem cell laboratory services company. The Company is in the process of completing a research collaboration with the Center for Equine Health and Stem Cell Regenerative Medicine Group at the University of California, Davis, School of Veterinary Medicine.
Under the collaboration, the Company's MarrowXpress(TM) System and BioArchive(R) System will be used for the processing and cryogenic storage of equine stem cells from cell rich sources, including fetal tissue and fluids during foaling, and bone marrow from yearlings and adults. The stem cells will be used in therapeutic treatment of orthopedic injuries in the performance equine market including Thoroughbreds, American Quarter Horses, and Arabians. The Company is currently refining collection and processing methodologies at large breeder farms in California, and expects to be in operation commencing with the 2009 foaling season, which begins in January of next year.
"The creation of Vantus, Inc. is a major milestone in our regenerative medicine diversification strategy that we began implementing several months ago. This program leverages the expertise and world renowned reputation of the UC Davis organization in animal research and our industry leading stem cell processing and storage technologies," noted Dr. William Osgood, Chief Executive Officer of ThermoGenesis.
"We have the potential to create a new paradigm for the treatment of injured performance horses using our unique approach of capturing stem cells when the horse is born up through the first year of life. This represents a potentially sizeable market opportunity for the Company in which we believe we can achieve a meaningful competitive advantage quickly. Equine stem cells are being used successfully to treat a number of injuries today, with the potential for significant and rapid growth given the early clinical efficacy of these treatments and relatively low regulatory hurdles in the veterinary market," he added.
"The collaborative support and assistance we will be receiving from Vantus should allow our scientists to move forward rapidly in the development of new and unique veterinary stem cell applications. We expect that their experience in the processing and bioarchival storage of stem cells, combined with the expertise of our research and clinical personnel, will provide compelling synergy for scientific discovery," said Dr. Gregory Ferraro, of the UC Davis Center for Equine Health.
Osgood noted, "In addition, the experience we gain in the veterinary stem cell market and the products and services that will come from research and innovations in harvesting, processing, and therapeutic treatments, will directly translate to treatment of human orthopedic injury and disease and speed our entry into this evolving market."
"Finally, we believe our wound healing technologies will have direct application in the veterinary market, which we expect will add additional revenues to the Company," he added.
To learn more about Vantus please log onto http://www.vantuslabs.com/
About ThermoGenesis Corp.
ThermoGenesis Corp. (http://www.thermogenesis.com/
) is a leading supplier of innovative products and services that process and store adult stem cells for treatment of disease and injury. These products include:
-- The BioArchive(R) System, an automated cryogenic device, is used by
cord blood stem cell banks in more than 25 countries for cryopreserving
and archiving cord blood stem cell units for transplant. GE Healthcare
is the nonexclusive global distribution partner for the BioArchive
-- AXP(TM) AutoXpress Platform (AXP(TM)) is a proprietary family of
automated devices that includes the AXP and the MarrowXpress(TM) and
companion sterile blood processing disposable for harvesting stem cells
in a closed system. The AXP device is used for the processing of cord
blood. GE Healthcare is the exclusive global distribution partner for
the AXP cord blood product. The MarrowXpress is used for isolating stem
cells from bone marrow. ThermoGenesis sells the MarrowXpress directly
to global customers.
-- The CryoSeal(R) FS System, an automated device and companion sterile
blood processing disposable, is used to prepare fibrin sealants from
plasma in about an hour. We received FDA approval to market the
CryoSeal FS System in liver resection surgeries in July 2007. The
CryoSeal FS System has received the CE-Mark. From a marketing
perspective, the CE Mark is the European equivalent to an FDA approval,
in that it allows sales of the product throughout the European
community. Asahi Medical is the exclusive distributor for the CryoSeal
System in Japan and the Company markets through independent
distributors in Europe and South America.
-- The Thrombin Processing Device(TM) (TPD(TM)) is a sterile blood
processing disposable that prepares activated thrombin from a small
aliquot of plasma in less than 30 minutes. The CE-Marked TPD is
currently being marketed in Europe by Biomet, Inc., subsidiary Biomet
Biologics, Medtronic, Inc. and independent distributors.
Web site: http://www.thermogenesis.com/
---------------------- It's easy! Just copy code below and paste into your webpage --------------------
<a href="http://www.equestrianmag.com/article/equine-health-stem-cell-regenerative-med-2-08.html">New Initiative to Address Equine Health & Veterinary Regenerative Medicine</a> ~ EquestrianMag.com